Berencsi K, Sami A, Ali MS, et al. - A total of 143 million person-years(PY) of follow-up and 76,141 incident episodes of SR treatment were involved in this study in order to ascertain the influence of risk minimization measures on the use of strontium ranelate in Europe. While the prevalence of restricted indications rose in these periods, the prevalence of any contraindication reduced. One-year persistence reduced in the evaluation in comparison with the reference period. The study shows a substantial influence of the regulatory action to modify the use of SR in Europe ie, SR utilization overall reduced robustly. Moreover, the proportion of individuals accomplishing the restricted indications, without contraindications, improved following the proposed risk minimization measures.